A plausible explanation for the limited activity of single-agent NAMPT inhibitors as cancer therapeutics in clinical trials could be the presence in human body fluids of NAD+ or NAD+ precursors, including nicotinic acid (NA), NMN and NR, which could well substitute for the inhibited NAD+ biosynthesis from NAM [25]. Here, NAMPT is linked to cancer.